RAS blockade at maximal tolerated dosage for 1 month,
eGFR (CKD-EPI) between 10 and 20 ml/min/1.73m2,
UACR \> 300mg/g creatinine and UPCR \> 500mg/g creatinine,
office systolic blood pressure \> 110 mmHg,
stable dosage of antihypertensive drugs and diuretics for 1 month.
for women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed.
You may not be if
any medical condition that, in the opinion of the investigator makes the participant not suitable for inclusion,
history of ketoacidosis in the past while on empagliflozin or any other SGLT2i class drugs,
participation in another clinical study with an investigational medicinal product (IMP) administered during the month before screening,
known hypersensitivity or intolerance to empagliflozin or any of the excipients of the product,
judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements,
no social insurance,
unwilling to give informed consent,
vulnerable persons (minors, adults under guardianship or trusteeship, pregnant women, persons deprived of their liberty, persons unable to speak French).
